Home | Screening data | Screen comparisons | Search for compounds | Structure search

Compound InformationSONAR Target prediction
Name:

GEMFIBROZIL

Unique Identifier:SPE01500313
MolClass: Checkout models in ver1.5 and ver1.0
Molecular Formula:
Molecular Weight:228.159 g/mol
X log p:5.329  (online calculus)
Lipinksi Failures1
TPSA26.3
Hydrogen Bond Donor Count:0
Hydrogen Bond Acceptors Count:3
Rotatable Bond Count:6
Canonical Smiles:Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1
Source:synthetic
Therapeutics:antihyperlipoproteinemic
Generic_name:Gemfibrozil
Chemical_iupac_name:5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid
Drug_type:Approved Drug
Pharmgkb_id:PA449750
Kegg_compound_id:C07020
Drugbank_id:APRD00293
Melting_point:61-63 oC
H2o_solubility:10 mg/mL (in base)
Logp:4.242
Cas_registry_number:25812-30-0
Drug_category:Antilipemic Agents; Fribic Acid Derivatives; ATC:C10AB04
Indication:For treatment of adult patients with very high elevations of serum triglyceride
levels (types IV and V hyperlipidemia) who are at risk of developing pancreatitis
(inflammation of the pancreas) and who do not respond adequately to a strict diet.
Pharmacology:Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat
hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia.
It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels
(moderately), and increase HDL levels (moderately).
Mechanism_of_action:Gemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby
increasing lipoprotein triglyceride lipolysis. Chylomicrons are degraded, VLDLs are
converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight
increase in secretion of lipids into the bile and ultimately the intestine.
Gemfibrozil also inhibits the synthesis and increases the clearance of
apolipoprotein B, a carrier molecule for VLDL.
Organisms_affected:Humans and other mammals

Found: 64 active | as graph: single | with analogs 2 3 4 5 6 7 8 9 10  Next >> [64]
Species: 4932
Condition: BCK1
Replicates: 2
Raw OD Value: r im 0.7390±0.0339411
Normalized OD Score: sc h 0.8228±0.0185743
Z-Score: -6.0362±0.0853258
p-Value: 0.00000000168637
Z-Factor: 0.332883
Fitness Defect: 20.2007
Bioactivity Statement: Active
Experimental Conditions
Library:Spectrum_ED
Plate Number and Position:3|B2
Drug Concentration:50.00 nM
OD Absorbance:595 nm
Robot Temperature:30.00 Celcius
Date:2010-08-10 YYYY-MM-DD
Plate CH Control (+):0.09575±0.00727
Plate DMSO Control (-):0.95175±0.01995
Plate Z-Factor:0.9054
png
ps
pdf

DBLink | Rows returned: 1
3463 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid

internal high similarity DBLink | Rows returned: 0

active | Cluster 4424 | Additional Members: 7 | Rows returned: 0

Service provided by the Mike Tyers Laboratory